How GLP-1 Drugs Like Semaglutide May Help Women with PCOS and Obesity | Research

The takeaway

GLP-1 receptor analogs show promising dual benefits for women with PCOS and obesity, improving both metabolic markers like insulin resistance and reproductive outcomes like ovulation.

Dual metabolic + reproductive benefits
GLP-1 analogs address insulin resistance, weight, androgens, and ovulation in PCOS

What the researchers found

GLP-1 receptor analogs demonstrate evidence of improving both metabolic dysfunction (insulin resistance, weight) and reproductive outcomes (androgen levels, ovulation) in women with PCOS and obesity.

Why it matters

PCOS affects up to 13% of reproductive-age women, and obesity makes it worse. If GLP-1 drugs can address both the weight and hormonal components simultaneously, it could transform PCOS management.

How the study worked

Evidence review/synthesis examining clinical data linking GLP-1 receptor analog therapy to metabolic and reproductive outcomes in PCOS patients with obesity.

What this study cannot tell us

Review article rather than original clinical trial; GLP-1 drugs are not yet approved specifically for PCOS; long-term reproductive safety data in this population is limited.

How to read the evidence

Evidence review synthesizing existing clinical data — provides strong rationale but not definitive proof from dedicated PCOS trials.

When this study was published

Published in 2026, capturing the latest evidence on GLP-1 drugs in PCOS as these medications gain broader clinical use.

The bigger picture

This positions GLP-1 drugs as potentially game-changing for PCOS beyond just weight loss, addressing the metabolic root cause that drives hormonal disruption and infertility in millions of women worldwide.

Questions still open

Should GLP-1 receptor analogs become a first-line treatment for PCOS in obese women?
How do GLP-1 drugs compare to metformin for improving fertility outcomes in PCOS?

Common questions

Can GLP-1 drugs like Ozempic help with PCOS?

Emerging evidence suggests yes — by improving insulin resistance and reducing weight, GLP-1 drugs may also help normalize hormone levels, reduce androgen excess, and restore ovulation in women with PCOS.

Are GLP-1 drugs approved for PCOS treatment?

Not yet specifically for PCOS. They are approved for diabetes and obesity, but growing evidence supports their off-label use in PCOS, particularly in women who also have obesity and insulin resistance.

Read the original research

GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity.

Obesity facts, 19(1), 93-108

View on PubMed ↗Publisher’s paper ↗

Citation

Celik, Ozlem; Yazici, Dilek; Ciudin, Andreea; Macut, Djuro; Micic, Dragan; Yumuk, Volkan; Yildiz, Bulent Okan. (2026). GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity.. Obesity facts, 19(1), 93-108. https://doi.org/10.1159/000547055